← Back to Home

Lilly to buy Calytrix Bio for up to $1.5 billion

Reuters

Nov 16 (Reuters) - Eli ‌Lilly has agreed to acquire Calytrix Bio for up to $1.5 ​billion ‌in cash to expand the development ‌of treatments for rare blood cancers, the privately held biotech said ‌on Monday.

The move is the latest in a string of acquisitions by the Indianapolis-based pharmaceutical giant as it ⁠works to diversify beyond its blockbuster ‌diabetes and weight-loss ⁠franchise, the company's primary growth engine.

The ​Calytrix transaction includes an upfront payment and additional payments tied to ​clinical trial and regulatory milestones. ​Calytrix ‌did not disclose the size of the ​upfront payment or the ⁠deal's expected closing date.

Calytrix's lead ‌candidate is ​an early-stage antibody ​treatment for essential thrombocythemia and myelofibrosis – rare blood disorders that cause the bone marrow to produce excessive abnormal ‌blood cells.

The deal is expected to strengthen Lilly's footprint in hematology, ‌adding ​an experimental treatment to a business that already includes the FDA-approved blood cancer medicine Jaypirca.

(Reporting by Padmanabhan Ananthan in ‌Bengaluru; Editing by Shailesh Kuber)